This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Linagliptin and Metformin combination is an oral medication that the Food and Drug Administration (FDA) approved on January 30, 2012. It is used for the treatment of type 2 diabetes to help control blood sugar levels. 

Mechanism of Action of undefined

Linagliptin, a DPP-4 inhibitor, works by increasing insulin release and decreasing glucagon secretion in response to meals, helping to lower blood sugar levels. Metformin, a biguanide, reduces glucose production in the liver and improves insulin sensitivity in muscle and fat tissues. Together, they enhance glycemic control by addressing different aspects of blood sugar regulation in people with type 2 diabetes.

Uses of undefined

Linagliptin and Metformin work together to improve blood sugar control in adults with type 2 diabetes mellitus. Doctors prescribe this combination when both medications are suitable for managing the condition along with diet and exercise.

undefined Drug administaration and Dosage available

The Linagliptin and Metformin combination is typically taken with food, either before or after a meal, to help reduce the risk of gastrointestinal side effects. It's important to follow the specific instructions provided by the healthcare provider regarding the timing of the dose.

Warnings, Precautions and Side Effects of undefined

Warnings

  • Lactic Acidosis Risk: Rare but serious and potentially life-threatening. Watch for symptoms like muscle pain, weakness, breathing difficulty, and abdominal discomfort. Monitor patients with kidney or liver issues, dehydration, or excessive alcohol use closely.
  • Renal Impairment: Avoid use in patients with severe kidney impairment or acute kidney injury. Regularly monitor kidney function during treatment.
  • Hypoglycemia: May cause low blood sugar, especially when combined with other diabetes medications (e.g., insulin or sulfonylureas). Recognise symptoms like shakiness, dizziness, and confusion.
  • Hepatic Impairment: Use caution in patients with liver disease and monitor liver function periodically. Discontinue the drug if liver problems develop.
    Heart Failure: Exercise caution in patients with heart failure, as metformin may worsen the condition.
  • Alcohol Use: Limit alcohol consumption, as excessive intake increases the risk of lactic acidosis and other complications.

Precautions

Patients should inform their healthcare provider about any kidney or liver issues, as these medications require careful monitoring in such conditions. Healthcare providers should use caution when prescribing to elderly patients or those with a history of heart failure. Patients should regularly monitor their blood sugar levels, as the combination may increase the risk of hypoglycemia when used with other diabetes medications.

Side Effects

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.

Common side effects of Linagliptin and Metformin:

  • Gastrointestinal issues (e.g., nausea, diarrhea, upset stomach)
  • Headache
  • Upper respiratory tract infections
  • Cough
  • Back pain

Serious side effects of Linagliptin and Metformin:

  • Lactic acidosis (a rare but serious condition, symptoms include muscle pain, weakness, and difficulty breathing)
  • Hypoglycemia (low blood sugar, especially when taken with other diabetes medications)
  • Severe allergic reactions (e.g., rash, itching, swelling)
  • Kidney problems (e.g., changes in urination, swelling in feet or ankles)
  • Liver problems (e.g., yellowing of the skin or eyes)

Word Of Advice

Follow your healthcare provider’s instructions on dosage and timing to control your blood sugar effectively. Take the medication with food to minimise gastrointestinal side effects. Regularly monitor your blood sugar and watch for signs of low blood sugar, especially if you're also using other diabetes medications. Stay hydrated and limit alcohol intake to reduce the risk of serious side effects.

Frequently Asked Question

References

1. Haak T. Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. https://pmc.ncbi.nlm.nih.gov/articles/PMC4284079/

2. Mu Y, Pan C, Fan B, Hehnke U, Zhang X, Zhang X, Wang X, Liu J, Zhang Y, Du J, Ma J, Gong Y. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes. Diabetes Res Clin Pract. https://pubmed.ncbi.nlm.nih.gov/28088030/

3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201281S014S018lbl.pdf

4. https://www.ema.europa.eu/en/documents/product-information/jentadueto-epar-product-information_en.pdf

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.